PMID- 30767729
OWN - NLM
STAT- MEDLINE
DCOM- 20200406
LR  - 20211204
IS  - 1557-8100 (Electronic)
IS  - 1536-2310 (Linking)
VI  - 23
IP  - 2
DP  - 2019 Feb
TI  - Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute 
      Promyelocytic Leukemia Treatment with Arsenic Trioxide.
PG  - 119-130
LID - 10.1089/omi.2018.0178 [doi]
AB  - The introduction of arsenic trioxide (ATO) in treatment of acute promyelocytic 
      leukemia (APL) has resulted in high clinical complete remission (CR) rates over 
      90%. On the contrary, the risk for early death (ED) in APL patients treated with 
      ATO continues to have a negative impact for optimization of APL therapeutics. 
      There is an urgent need for precision medicine and biomarkers in clinical 
      monitoring of ATO toxicity in APL, and ED in particular. This retrospective case 
      series cohort proteomics study was conducted as a hypothesis generation effort 
      and provides here several potential molecular leads on serum peptides expressed 
      at different times after treatment with ATO in patients with APL. In 12 patients 
      with a de novo APL diagnosis, and treated with single-agent ATO as frontline 
      remission induction therapy, serum peptides were fractionated by weak cation 
      exchange magnetic beads and analyzed by matrix-assisted laser 
      desorption/ionization time-of-flight mass spectrometry. Ten peptides (m/z 2075.5, 
      2084.2, 2203.0, 2265.2, 2872.8, 2916.6, 3145.2, 3153.4, 3953.4, and 3964.8) were 
      significantly downregulated in serum after ATO treatment. Among them, four 
      peptides were identified as (1) Immunoglobulin heavy chain V-III region BUT, (2) 
      RRP15-like protein, (3) filaggrin, and (4) protein SON isoform F. To the best of 
      our knowledge, this is the first clinical oncology proteomic biomarker study with 
      a view to future rational therapeutic monitoring of patients with APL in the 
      course of single-agent ATO treatment and hematological CR.
FAU - Cao, Fenglin
AU  - Cao F
AD  - 1 Department of Central Laboratory, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, China.
FAU - Li, Xingang
AU  - Li X
AD  - 2 School of Medical and Health Sciences, Edith Cowan University, Perth, 
      Australia.
FAU - Yang, Yiju
AU  - Yang Y
AD  - 3 The Third People's Hospital of Hainan Province, Sanya, China.
FAU - Fang, Honghong
AU  - Fang H
AD  - 4 Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, 
      Capital Medical University, Beijing, China.
FAU - Qu, Haixia
AU  - Qu H
AD  - 5 Bioyong (Beijing) Technology Co., Ltd., Beijing, China.
FAU - Chang, Naibai
AU  - Chang N
AD  - 6 Department of Hematology, Beijing Hospital, Beijing, China.
FAU - Ma, Qingwei
AU  - Ma Q
AD  - 5 Bioyong (Beijing) Technology Co., Ltd., Beijing, China.
FAU - Cao, Weifan
AU  - Cao W
AD  - 7 College of Life Science, Northeast Forest University, Harbin, China.
FAU - Zhou, Jin
AU  - Zhou J
AD  - 8 Department of Hematology, The First Affiliated Hospital, Harbin Medical 
      University, Harbin, China.
FAU - Wang, Wei
AU  - Wang W
AD  - 2 School of Medical and Health Sciences, Edith Cowan University, Perth, 
      Australia.
AD  - 4 Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, 
      Capital Medical University, Beijing, China.
AD  - 9 School of Public Health, Taishan Medical University, Taishan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - OMICS
JT  - Omics : a journal of integrative biology
JID - 101131135
RN  - 0 (Biomarkers)
RN  - 0 (FLG protein, human)
RN  - 0 (Filaggrin Proteins)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Arsenic Trioxide/*therapeutic use
MH  - Biomarkers/*blood
MH  - Filaggrin Proteins
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/*blood/*drug therapy
MH  - Precision Medicine
MH  - Proteomics/*methods
MH  - Retrospective Studies
OTO - NOTNLM
OT  - acute promyelocytic leukemia
OT  - arsenic trioxide
OT  - biomarkers
OT  - precision medicine
OT  - proteomics
OT  - therapeutic drug monitoring
EDAT- 2019/02/16 06:00
MHDA- 2020/04/09 06:00
CRDT- 2019/02/16 06:00
PHST- 2019/02/16 06:00 [entrez]
PHST- 2019/02/16 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
AID - 10.1089/omi.2018.0178 [doi]
PST - ppublish
SO  - OMICS. 2019 Feb;23(2):119-130. doi: 10.1089/omi.2018.0178.